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Introduction
Finding new therapeutic modalities for the treatment of cancer 
remains one of the most relevant tasks in medicinal chemis-
try. Post-transcriptional downregulation of genes by a natural 
process called RNA interference (RNAi) is currently explored 
as a novel medical treatment option.1 RNAi is triggered by 
double-stranded RNA.2 Most frequently, short interfering RNA 
(siRNA) consisting of 21–23 nucleotides are used to modulate 
gene expression. Although it has been shown very clearly by 
experiments with cells in culture3 that siRNA mediated gene 
silencing is very specific and efficient once the nucleic acid 
has entered the cytosol, one challenge for the development 
of  efficient  siRNA  therapeutics  remains:  the  delivery  pro-
cess.4 In intravenous administration of siRNA therapeutics, 
besides insufficient cellular uptake and unspecific delivery, 
degradation in the bloodstream as well as rapid renal clear-
ance  are  major  limitations.  Polycationic  compounds  have 
shown to act as efficient carrier systems for different classes 
of nucleic acids. Ionic interactions between those polymers 
and the negatively charged phosphate backbone of nucleic 
acids result in the formation of nanoparticles, called poly-
plexes. These structures can efficiently protect siRNA during 
circulation in blood and enable interactions with cell surfaces. 
Improved carriers incorporate polyethylene glycol (PEG) to 
shield  the  positive  surface  charge  of  polyplexes,  reducing 
unspecific interaction with blood compounds and non-target 
cells. For specific target cell recognition, ligands can be cova-
lently attached to the polyplex structure allowing for interac-
tions with highly expressed target cell surface receptors. In a 
different approach PEG and/or targeting ligands have been 
covalently attached to the siRNA backbone.5–8 Both concepts 
have shown to result in a significant increase in transfection 
efficiency.9 Due to high polydispersity of the used polymers 
(polycation and PEG) and limited options in chemical ligation 
and purification, such systems often lack precise structural 
definition. Thus, a clear evaluation of structure activity rela-
tionships is hampered. Moreover, reproducible production of 
materials for clinical trials can prove difficult due to significant 
batch to batch variations and lack of accurate analytics.
Results
The current work aims at the design of a carrier system exclu-
sively composed of precisely defined, pure compounds allow-
ing for a clear structure activity relationship. Consequently, we 
combined a covalent siRNA-PEG-ligand conjugate with a pre-
cise monodisperse three-armed polycation to form a polyplex. 
As targeting ligand, folic acid was chosen, due to its small size, 
high-binding affinity to its receptor (10−10 mol/l) and the upregu-
lation of the folic acid receptor in many tumor types.10–12 The 
synthesis of the PEGylated targeting ligand was performed by 
solid phase supported peptide chemistry (Figure 1a). For the 
introduction of PEG, a commercially available monodisperse 
PEG consisting of 24 ethylene glycol units was used. Supple-
mentary Figure S1 and S2 demonstrate identity and purity by 
mass spectrum and high performance liquid chromatography, 
respectively. The targeting ligand contains an azide linker to 
enable the covalent attachment of siRNA by Cu(I) catalyzed 
1,3-dipolar cycloaddition, since the siRNA is equipped with 
an alkyne linker at the 5′-end of its sense strand (Figure 1a). 
After purification by ion exchange chromatography, the desired 
structure was obtained in high purity, as demonstrated by gel 
shift assay (Figure 1b, c) and mass spectrum (Supplemen-
tary Figure S3). Flow cytometry (Figure 2) and fluorescence 
microscopy using 5′-labeled siRNA (Cy5 fluorophore at 5′-end 
of the antisense strand, Figure 3) revealed that the attachment 
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of folic acid to the siRNA enabled specific and very efficient 
receptor mediated uptake into folic acid receptor expressing 
KB cells without the need of any additional carrier. Specificity 
was demonstrated by preincubation of cells with free folic acid 
inhibiting cellular uptake of the siRNA conjugate. Furthermore, 
Neuro2A cells with a low folic acid receptor level remained 
untransfected. In addition, control conjugates such as PEGy-
lated or unconjugated siRNA were not able to enter the target 
cell. As the targeted siRNA conjugate was shown to be taken 
up  by  receptor-mediated  endocytosis,  gene  silencing  effi-
ciency of the modified siRNA was tested. At first we checked 
whether the covalent siRNA modifications (FolA-PEG-siGFP, 
PEG-siGFP)  are  compatible  with  the  RNAi  machinery.  For 
this we performed a receptor-independent transfection assay 
in Neuro2A cells (stably expressing the enhanced green fluo-
rescent protein (eGFP)-luciferase fusion gene) using cationic 
lipopolymer 230 as potent but nonspecific transfection agent 
(Supplementary  Figure  S4).13,14  Irrespective  of  the  siRNA 
Figure 1  Synthesis of the defined FolA-PEG-siRNA conjugate. (a) Synthesis of folic acid targeted PEG-ligand by solid phase supported 
peptide synthesis and its conjugation to siRNA via Cu(I) catalyzed 1,3-dipolar cycloaddition. (b) Chromatogram of the ion exchange chro-
matographic purification of a FolA-PEG-siRNA   conjugate. The purification was carried out on a Resource Q column (1 ml; GE Healthcare, 
Freiburg, Germany) connected to an Äkta Basic system (detection wavelength: 260 nm). After loading the column using 20 mmol/l HEPES, 
pH 6.5, 20 mmol/l NaCl, 30% acetonitrile,   elution was achieved employing a sodium chloride gradient of 10 mmol/l NaCl/minute and a flow 
rate of 1 ml/minute. (c) Agarose gel shift   assay of the fractions collected during ion exchange chromatographic purification of a FolA-PEG-
siRNA conjugate. Fractions were   collected and analyzed using a 2.5% agarose gel (100 V, 100 minutes). C: Unconjugated input siRNA, 
numbers above indicate the individual fractions. Fraction size 0.5 ml. PEG, polyethylene glycol; siRNA, small interfering RNA.
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Figure 2  Histogramm of receptor mediated uptake of FolA-
PEG-siRNA analyzed by flow cytometry. (a) KB cells, I: untrans-
fected  cells,  II:  FolA-PEG-siRNA  with  folic  acid  competition,  III: 
PEG-siRNA, IV: FolA-PEG-siRNA; (b) folic acid receptor negative 
Neuro2A cells, I: untransfected cells, II: FolA-PEG-siRNA. siRNA, 
small interfering RNA.
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Figure  3  Fluorescence  microscopic  images  of  receptor-
  specific cellular uptake. (a–c) Fluorescence microscope images 
of the cellular uptake of Cy5-labeled siRNA into folic acid receptor 
positive KB cells or (d) Neuro2A control cells with low folic acid 
receptor level. (a,d) Transfection with FolA-PEG-siRNA; (b) Trans-
fection with   FolA-PEG-siRNA after preincubation with free folic acid; 
(c) Transfection with PEG-siRNA lacking the FolA ligand. siRNA, 
small   interfering RNA.www.moleculartherapy.org
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construct employed, silencing activity was similar compared 
to unconjugated siRNA. Thus, the siRNA was not negatively 
affected by the modification. Next we tested folate receptor-tar-
geted transfer. Although it was proven that FolA-PEG-siRNA is 
taken up intracellularly into folic acid receptor positive KB cells 
and the PEG polymer conjugation does not negatively affect 
the  siRNA  silencing  potential,  the  use  of  plain  FolA-PEG-
siGFP conjugate did not result in reporter gene silencing (data 
not shown). This finding is consistent with data in the literature 
where siRNA conjugated to folic acid was found to be taken up 
by endocytosis, but did not result in significant gene silencing.7 
This compound was found trapped in intracellular vesicles and 
thus, lacking endosomal escape functionality, does not have 
access  to  the  RNA  induced  silencing  complex  in  the  cell’s 
cytosol, which is necessary for a RNAi effect. To combine our 
selective targeting siRNA molecule with an agent enabling effi-
cient endosomal escape, it was complexed with the recently 
described   monodisperse polycationic carrier 386. This non-
toxic molecule13 is also based on solid phase supported car-
rier design (Figure 4).13–15 The carrier is composed of three 
arms, each built out of three succinoyl-tetraethylenpentamine 
(Stp) units, connected via a branching lysine, and terminated 
by cysteines at the termini which are essential for polyplex 
stabilization  by  disulfide  formation  after  particle  formation 
(  Figure 4). In the current work it was used to build polyplexes 
with the targeted siRNA conjugate, to protect it in the extracel-
lular environment and to mediate endosomal escape by the 
proton sponge ability of its polyethylenimine-like 1,2-diamino-
ethane units.16,17 By gel retardation (Supplementary Figure 
S5) stable particle formation was confirmed. PEGylated siRNA 
reduced the zeta potential of these polyplexes from 20 mV to 
11–14 mV (~30–45% reduction), which indicates that the PEG 
spacer and thus also the targeting ligand is presented on the 
polyplex surface (Supplementary Table S1). Targeting speci-
ficity was retained as proven by flow cytometry experiments 
using folic acid receptor positive KB cells (Supplementary 
Figure S6). Transfecting KB eGFP-luc cells with FolA-PEG-
siGFP bearing polyplexes resulted in significant reporter gene 
silencing   (Figure 4). Even mixtures of conjugated and uncon-
jugated siRNA in one polyplex formulation (indicated as % 
targeted siRNA) lead to significant knockdown. A minimum of 
1% FolA-PEG conjugated siRNA was necessary to observe a 
significant targeting ligand effect, 5% conjugated siRNA was 
sufficient for a maximal knockdown. In contrast, polyplexes 
formed with PEGylated siRNA lacking the targeting ligand or 
unconjugated siRNA did not result in reporter gene silencing 
at any tested ratio of mixture. With the targeted polyplex formu-
lation, potent gene silencing was observed at 25–200 nmol/l 
siRNA, but significant downregulation of the target gene of 
more than 50% was still observed at the further reduced 12.5 
nmol/l siRNA concentration (Supplementary Figure S7).
Discussion
We  report  targeted  siRNA  polyplexes  consisting  of  two 
molecularly  precise  components:  a  covalent  siRNA  conju-
gate equipped with a folic acid receptor targeting ligand and 
PEG shielding function, together with a defined three-arm 
polycation  for  siRNA  packaging  and  nanoparticle  forma-
tion. The synthesis of the single components by solid phase 
Figure 4  Receptor-specific reporter gene silencing of FolA-PEG-siRNA in combination with the defined polycation 386. (a) Defined 
polycationic carrier 386 synthesized by solid phase chemistry and used for polyplex formation. (b) siRNA mediated silencing of the reporter 
fusion gene eGFP-luciferase using polyplexes with different mixtures of targeted and nontargeted siRNA (% of targeted siRNA in total siRNA) 
using polycation 386 (at N/P of 6). Final siRNA concentration: 200 nmol/l. Data are presented as mean ± SD. eGFP, enhanced green fluores-
cent protein; N/P, nitrogen/phosphate; siRNA, small interfering RNA.
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chemistry resulted in a defined targeting macromolecule. The 
use of Cu(I) catalyzed 1,3-dipolar cycloaddition allowed the 
construction of a very pure and defined siRNA conjugate, its 
purification and analysis. Combining this structure with the 
defined  polycationic  carrier  molecule  386,  which  contains 
polyethylenimine-like 1,2-diaminoethane units for endosomal 
buffering and release, leads to efficient and specific reporter 
gene silencing in folic acid receptor positive KB cells. The 
presented data make this carrier system a promising candi-
date for further in vivo gene silencing applications.
Materials and methods
Nucleic  acids.  Oligoribonucleotides  were  synthesized  on 
solid phase according to standard phosphoramidite oligomer-
ization  methodology.  Commercially  available  5′-O-(4,4′-
dimethoxytrityl)-3′-O-(2-cyanoethyl-N,N-diisopropyl) 
phosphoramidite monomers of uridine (U), 4-N-acetylcyti-
dine (CAc), 6-N-benzoyladenosine (Abz), and 2-N-isobutyr-
lguanosine  (GiBu)  with  2’-O-t-butyldimethylsilyl  protected 
phosphoramidites were used. 2′-O-methyl modifications were 
introduced employing the corresponding phosphoramidites 
carrying the same protecting groups as the regular building 
blocks; 5-ethyl thiotetrazole (500 mmol/l in acetonitrile) was 
used as activator solution for phosphoramidite couplings. In 
order to introduce phosphorothioate linkages a 50 mmol/l 
solution  of  3-((dimethylamino-methylidene)amino)-3H-1,2, 
4-dithiazole-3-thione (obtained from AM Chemicals, Ocean-
side, CA) in anhydrous acetonitrile/pyridine (1:1 vol/vol) was 
employed. The linker on the 5′-end of the sense strand was 
generated without any modification of the synthesis cycle 
using 1-O-dimethoxytrityl-hexyl-disulfide,1’-[(2-cyanoethyl)-
(N,N-diisopropyl)]-phosphoramidite  followed  by  coupling 
of  6-hexyn-1-yl-(2-cyanoethyl)-(N,N-diisopropyl)-phophor-
amidite  to  the  5′-terminus.  Both  linker  amidiates  were 
obtained from Glen Research (Sterling, VA). After cleavage 
and de-protection,18 RNA oligonucleotides were purified by 
anion-exchange  high  performance  liquid  chromatography 
and  characterized  by  MALDI  or  ES  mass  spectrometry. 
To generate siRNAs from RNA single strands, equimolar 
amounts of complementary sense and antisense strands 
were mixed and annealed in a 20 mM NaCl, 4 mM sodium 
phosphate pH 6.8 buffer. siRNAs were further character-
ized by capillary gel electrophoresis and were stored frozen 
until use.
For cell culture experiments a siRNA directed against eGFP 
(siGFP, sense sequence: Hexynyl-C6-ss-C6-5’-AuAucAuGGc 
cGAcAAGcAdTsdT-3’;  antisense  sequence:  5’-UGCUUGU 
CGGCcAUGAuAUdTsdT-3’;  small  letters:  2’-methoxy-RNA; 
s: phosphorothioate) or an unrelated control siRNA (siCtrl, 
sense sequence: Hexynyl-C6-ss-C6-5’-AuGuAuuGGccuGuAu 
uAGdTsdT-3’;  antisense  sequence:  5’-CuAAuAcAGGCcA 
AuAcAUdTsdT-3’)  was  used.  As  additional  unconjugated 
control  siRNA,  the  same  sequences  without  modifica-
tion at the 5’-end of the corresponding sense strands were 
used. Uptake studies by fluorescence-activated cell sorting 
and fluorescence microscopy were performed using a Cy5 
labeled  siRNA  directed  against  the  house  keeping  gene 
AHA1 (siAHA1, sense sequence: Hexynyl-C6-ss-C6-5′-GGAu 
GAAGuGGAGAuuAGudTsdT-3′; antisense sequence: (Cy7-
NH-C6-5′-ACuAAUCUCcACUUcAUCCdTsdT-3’).
Loading of a 2-chlorotrityl chloride resin. All synthesis steps 
on solid support were carried out using a 5 ml syringe reactor 
connected to a vacuum pump.
For loading, the 2-chlorotrityl chloride (2-CTC) resin (1.6 
mmol chloride/g resin; Iris Biotech, Marktredwitz, Germany) 
was  swollen  in  anhydrous  dichloromethane  (DCM)  for  10 
minutes;  0.45  equivalents  (150%  of  the  desired  loading) 
of  Fmoc  protected  (S)-5-azido-2-(amino)pentanoic  acid 
  (Sigma-Aldrich,  Steinheim,  Germany)  and  0.9  equivalent 
N,N-diisopropylethylamine (DIPEA) per gram resin were dis-
solved in anhydrous DCM, added to the swollen resin and 
incubated for 1 hour under constant shaking. To cap residual 
reactive  chloride  groups  a  mixture  of  DCM/MeOH/DIPEA 
(80/15/5, vol/vol/vol) was added twice for 30 minutes. After 
washing the resin five times with DCM the loading of the 
resin was determined by Fmoc removal and measuring the 
absorbance at 301 nm. For Fmoc deprotection the resin was 
incubated four times for 10 minutes in 20% piperidine in N,N-
dimethylformamide (DMF). For short time storage, the resin 
was washed three times with DMF, DCM, and n-hexane and 
dried under vacuo.
Synthesis  of  FolA-PEG-azide.  After  swelling  (S)-5-azido-
2-(amino)pentanoic  acid  loaded  2-CTC  resin  (loading:  0.3 
mmol/g) in DCM for 30 minutes, HO-dPEG24-Fmoc (Quanta 
Biodesign,  Powell,  OH),  tBu-Glu(OH)-Fmoc  and  N10-
(trifluoroacetyl)pteroic acid (Clausson & Kaas, Farum, Den-
mark) were attached consecutively using amino acid/HoBt/
PyBop/DIPEA (4/4/4/8) in 1 ml DCM/DMF (1/1; vol/vol) and 
an incubation time of 1 hour. To cleave the Fmoc groups the 
resin was washed three times with DCM and three times 
with DMF and subsequently the resin was incubated four 
times with 20% piperidine in DMF for 10 minutes each. Cou-
pling of the amino acid as well as cleavage of the protective 
group was checked by Kaiser test.19 After coupling of N10-
(trifluoroacetyl)pteroic acid the resin was washed five times 
with DMF, five times with DCM, and incubated four times for 
30 minutes with 1 mol/l ammonium hydroxide solution/DMF 
(1:1,  vol/vol)  to  cleave  the  trifluoroacetyl  (TFA)  protecting 
group. After completion of the reaction the resin was washed 
three times with DCM and three times with n-hexane and 
finally dried in vacuo.
The desired targeting ligand was cleaved of the resin using 
a  cocktail  comprising  of  TFA/H2O/Triisopropylsilane  (TIS) 
(95.0/2.5/2.5; vol/vol/vol). After 2 hours the solution was col-
lected by filtration and the resin was washed twice with TFA 
and once with DCM. After reducing the volume by evapora-
tion, the solution was dropped slowly into a 1:1 mixture (40 
ml) of ice-cold Methyl-tert-butyl-ether (MTBE) and n-hexane. 
The resulting precipitate was centrifuged at 4 °C for 10 min-
utes (2,000–3,000 rpm). The solvents were decanted and 
the pellet was washed twice with ice-cold MTBE. The pellet 
was dissolved in 50% acetonitrile and lyophilized.
The  structural  analogue  dPEG24-azide  was  synthesized 
the same way, stopping the solid phase synthesis after cou-
pling of HO-PEG24-Fmoc and removing its protection group. www.moleculartherapy.org
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All structures were analyzed for purity by reverse phase-high 
performance  liquid  chromatography  and  identity  was  con-
firmed by mass spectrometry.
Synthesis  and  purification  of  FolA-PEG-siRNA.  74  nmol 
siRNA (modified with a hexynyl-ss-C6-linker at the 5′ end of 
its sense strand) in 100 µl H2O were mixed with 296 nmol 
FolA-PEG24-Azide in 300 µl dimethyl sulfoxide (DMSO)/t-
butanol (3/1; (vol/vol)) and 60 µl Tris[(1-benzyl-1H-1,2,3-tri-
azol-4-yl)methyl] (TBTA)/CuBr solution (0.1 mol/l TBTA/0.1 
mol/l CuBr 2/1 (vol/vol)) each in DMSO/t-butanol (3/1 (vol/
vol)). After 3 hours at 37 °C under constant shaking, the 
mixture was diluted with 1.5 ml buffer A (20 mmol/l HEPES, 
pH 6.5, 30% acetonitrile) and centrifuged for 5 minutes at 
13,000 rpm. The siRNA conjugate in the supernatant was 
purified using a 1 ml Resource Q column (GE Healthcare, 
Freiburg, Germany) connected to an Äkta basic system. For 
that purpose the supernatant was loaded onto the column 
using buffer A containing 20 mmol/l NaCl. After unbound 
material was washed away, the product was eluted setting 
a gradient of 10 mmol/l NaCl/minute and a flow rate of 1 ml/
minute. Fractions showing absorption at 260 nm were ana-
lyzed by a gel shift assay. For this the samples were loaded 
in a 2.5% agarose gel; 100 V were applied for 100 minutes. 
Samples showing a retarded migration on the gel compared 
to unconjugated input siRNA were pooled.
Synthesis of polycationic carriers. Synthesis of the polyca-
tionic  carriers  230  and  386  was  performed  as  described 
elsewhere.13
Mass spectrometry
Peptides. Peptidic compounds (1 mg) were dissolved in 1 ml 
H2O containing 0.1%TFA; 4 µl of this solution were spotted 
on a 4 µl matrix droplet consisting of a saturated solution 
of 2,5-dihydroxybenzoic acid in 50% acetonitrile contain-
ing 0.1%TFA. Samples were analyzed using an Autoflex II 
mass spectrometer (Bruker Daltonics, Bremen, Germany). 
Fifty to 100 spectra of respective probes were averaged for 
one sample spectrum.
Nucleic acid constructs. Samples were used as collected after 
ion exchange purification. To minimize additional salt peaks, 
5 µl of the samples were desalted by drop dialysis using an 
ultrafiltration membrane (Millipore, Billerica, MA) on a petri 
dish filled with H2O for 2 hours; 4 µl of this solution was spot-
ted on a 4 µl matrix droplet consisting of a saturated solution 
of 3-hydroxy picolinic acid in 50% acetonitrile. Samples were 
analyzed  using  an  Autoflex  II  mass  spectrometer  (Bruker 
Daltonics). Fifty to 100 spectra of respective probes were 
averaged for one sample spectrum.
Analytical reverse phase-high performance liquid chromatography. 
Analysis of the peptide synthesis products was performed 
on a Sunfire C18 column (5 µm, 4.6 × 150 mm) connected 
to a Waters high performance liquid chromatography system 
(Waters, Milford, MA). In a standard procedure the product 
was diluted in water containing 0.1% (vol/vol) TFA to a con-
centration of 1 mg/ml; 30 µl of this solution was loaded onto 
the column using a water/acetonitrile (0.1% TFA) mixture 
of 95:5 and a flow rate of 1 ml/minute for 5 minutes. The 
product was eluted using a water/acetonitrile gradient from 
95:5 to 0:100 in 30 minutes using a detection wavelength 
of 220 nm.
Polyplex formation. Polyplexes for transfections and gel shift 
experiments  were  prepared  as  follows,  unless  otherwise 
indicated:  270  ng  siRNA  (final  concentration:  200  nmol/l) 
and the calculated amount of polymer at indicated proton-
able nitrogen/siRNA phosphate ratios (N/P of 6, 12, or 20) 
were diluted in separate Eppendorf tubes, containing 10 µl of 
20 mmol/l HEPES buffered 5% glucose pH 7.4 (HBG) each. 
Polycation solution was added to the siRNA solution, rap-
idly mixed by pipetting up and down (at least five times) and 
incubated for 40 minutes at room temperature in order to 
form polyplexes.
Agarose gel shift assay. A 2% agarose gel was prepared by 
dissolving agarose in TBE buffer (trizma base 10.8 g, boric 
acid 5.5 g, disodium EDTA 0.75 g, and 1 l of water). GelRed 
was added for the detection of nucleic acids. Polyplexes in 20 
µl HBG and loading buffer (prepared from 6 ml of glycerine, 
1.2 ml of 0.5 mol/l EDTA, 2.8 ml of H2O, 0.02 g xylene cyanol) 
were filled into the sample pockets. Electrophoresis was per-
formed at 80 V for 40 minutes.
Measurement of particle size and zeta potential. Particle size 
of siRNA polyplexes was measured by laser-light scattering 
using a Zetasizer Nano ZS (Malvern Instruments, Worces-
tershire, UK). Polyplexes, containing 10 µg siRNA, were pre-
pared in 370 µl HEPES (20 mmol/l, pH 7.4) and filled up with 
HEPES (20 mmol/l, pH 7.4) to 1 ml before measurement.
Cell  culture.  Human  KB/eGFP-luc  cells,  stably  transfected 
with an eGFP-luciferase fusion gene, were grown in folate 
free RPMI-1640 medium, supplemented with 10% fetal calf 
serum (FCS), 4 mmol/l stable glutamine, 100 U/ml penicil-
lin, and 100 µg/ml streptomycin. Murine Neuro2A/eGFP-luc 
cells, stably transfected with a eGFP-luciferase fusion gene, 
were grown in Dulbecco’s modified Eagle medium, supple-
mented with 10% FCS, 4 mmol/l stable glutamine, 100 U/ml 
penicillin, and 100 µg/ml streptomycin.
Transfection. Transfection was performed in 96-well plates 
with 5 × 103 cells per well in triplicate. Cells were seeded 
24 hours before transfection and then medium was replaced 
with 80 µl fresh growth medium containing 10% FCS. siRNA 
polyplexes at indicated N/P ratios in 20 µl of HBG were added 
to each well and incubated at 37 °C. After 30 minutes medium 
change was performed. 48 hours after transfection cells were 
treated with 100 µl cell lysis buffer (25 mmol/l Tris, pH 7.8, 2 
mmol/l EDTA, 2 mmol/l DTT, 10% glycerol, 1% Triton X-100). 
Luciferase activity in the cell lysate was measured using a 
luciferase assay kit (100 µl luciferase Assay buffer; Promega, 
Mannheim,  Germany)  and  a  Lumat  LB9507  luminometer 
(Berthold, Bad Wildbad, Germany). Relative light units were 
presented as percentage of the luciferase gene expression of 
buffer treated control cells.Molecular Therapy–Nucleic Acids
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Flow cytometric assay. KB/eGFPLuc or Neuro2A/eGFPLuc 
cells were seeded into 24-well plates at a density of 5 × 
104 cells/well. After 24 hours, culture medium was replaced 
with  400  µl  fresh  growth  medium,  containing  10%  FCS. 
Plain Cy5-labeled siRNA (2.5 µg in 100 µl HBG) or trans-
fection complexes (N/P ratio of 6 and 12 in 100 µl HBG, 
containing 2.5 µg Cy5-labeled siRNA) were added to each 
well and incubated at 37 °C for 30 minutes. Subsequently, 
cells were washed twice with 500 µl phosphate-buffered 
saline. Cells were detached with trypsin/EDTA, taken up in 
phosphate-buffered saline with 10% FCS and flow cytom-
etry  was  performed  using  a  Cyan  ADP  flow  cytometer 
(Dako, Hamburg, Germany). Cellular uptake was assayed 
by excitation of Cy5 at 635 nm and detection of emission at 
665 nm. To discriminate between viable and dead cells as 
well as for exclusion of doublets, cells were appropriately 
gated by forward/sideward scatter and pulse width, coun-
terstained with 4′,6-diamidino-2-phenylindole (DAPI) and 1 
× 104 gated events per sample were collected. Data were 
recorded by SummitT software (Summit, Jamesville, NY) 
and evaluated using FlowJoT software.
Fluorescence microscopy. KB/eGFP-Luc or Neuro2A/eGFP-
Luc cells were seeded into 8 well Labtek chamber slides at a 
density of 2 × 104 cells/well. After 24 hours, culture medium 
was  replaced  with  240  µl  fresh  growth  medium,  contain-
ing  10%  FCS.  Cy5-labeled  siRNA  (1.5  µg  in  60  µl  HBG) 
was added to each well and incubated at 37 °C for 30 min-
utes.  Subsequently,  cells  were  washed  twice  with  500  µl 
phosphate-buffered saline and cell nuclei were stained with 
Hoechst 33342 dye. Cellular uptake was assayed by excita-
tion of Cy5 at 635 nm and detection of emission at 665 nm. 
An Axiovert 200 fluorescence microscope was used to collect 
the images and data were analyzed and processed by Axio-
Vision LE software (Zeiss, Jena, Germany).
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polyplexes.
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